Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05526911
Other study ID # TBAJ-876-CL002
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date July 20, 2022
Est. completion date August 28, 2022

Study information

Verified date May 2023
Source Global Alliance for TB Drug Development
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Phase 1, Drug-Drug Interaction Study to Evaluate the Safety, Tolerability, and the Induction Potential of TBAJ-876 on CYP3A4 and P-glycoprotein and the Inhibition Potential of TBAJ-876 on P-glycoprotein in Healthy Adult Subjects


Description:

This study is a two-part, open-label drug-drug interaction study conducted in one study center in the United States. Two groups are planned, Group 1 and Group 2. Group 2 will be conducted based on the Group 1 results. Group 1 will assess the induction potential of TBAJ-876 on the sensitive CYP3A4 substrate midazolam (M) and inhibition and induction potential of TBAJ-876 on the sensitive P-glycoprotein substrate Digoxin (D). Group 2 will only be conducted if the results of Group 1 show that TBAJ-876 is a moderate inducer of either CYP3A4 (midazolam AUC <0.50 when co-administered with TBAJ-876) or P-glycoprotein (digoxin AUC <0.50 when co-administered with TBAJ-876) or a moderate inhibitor of P-glycoprotein (digoxin AUC ≥2.0 when co-administered with TBAJ-876. This group will quantify the magnitude of inhibition or induction of TBAJ-876 on the antiretroviral regimen TLD, a fixed dose combination of tenofovir disoproxil fumarate (TFD), lamivudine (3TC) and dolutegravir (DTG), a regimen likely to be used in future clinical studies of TBAJ-876 by subjects living with HIV. Safety will be assessed throughout the study for all subjects. Safety assessments will include physical examinations, vital signs, serial ECGs, adverse events (AEs), clinical and laboratory tests (including hematology, serum chemistry, coagulation, and urinalysis).


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date August 28, 2022
Est. primary completion date August 28, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Key Inclusion Criteria: - Is a healthy adult male or female, 18 to 55 years of age (inclusive) at the time of screening. - Has a body mass index (BMI) =18.5 and =32.0 (kg/m2) and a body weight of no less than 50.0 kg at the time of screening and check-in. - Is medically healthy with no clinically significant screening results (e.g., laboratory profiles normal or up to Grade 1 per Division of Microbiology and Infectious Diseases (DMID) Toxicity Tables), as deemed by the Investigator. - Has not used tobacco- or nicotine-containing products (including smoking cessation products), for a minimum of 6 months before dosing. - Is willing and able to consume the entire high-calorie, high-fat breakfast meal in the timeframe required. Key Exclusion Criteria: - History or presence of significant cardiovascular abnormalities, heart murmur, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease as determined by the Investigator to be clinically relevant. - Any musculoskeletal abnormality (severe tenderness with marked impairment of activity) or musculoskeletal toxicity (frank necrosis). - Positive results at screening for Human Immunodeficiency Virus (HIV), Hepatitis B Surface Antigen (HBsAg), or Hepatitis C antibodies (HCV). - Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) results within 6 days prior to Day 1. - Current or history of prolonged QT syndrome. - Family history of Long-QT Syndrome or sudden death without a preceding diagnosis of a condition that could be causative of sudden death (such as known coronary artery disease, congestive heart failure or terminal cancer). - Use of any drugs or substances known to be inducers of CYP enzymes and/or P-gp, including St. John's Wort, within 30 days prior to the first dose of study drug. - Is lactose intolerant. - History or presence of allergic, or adverse response to midazolam, digoxin, dolutegravir, tenofovir, lamivudine or any related drugs.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
TBAJ-876
Day 6 to Day 13: 200 mg TBAJ-876 oral suspension, fed Day 14 to Day 19: 165 mg TBAJ-876 oral suspension, fed Day 20 and Day 21: 200 mg TBAJ-876 oral suspension, fasting Day 22 to Day 24: 150 mg TBAJ-876 oral suspension, fed
TBAJ-876
Day 6 to Day 13: 200 mg TBAJ-876 oral suspension, fed Day 14 to Day 19: 165 mg TBAJ-876 oral suspension, fed Day 20: 200 mg TBAJ-876 oral suspension, fasting Day 21 to Day 24: 150 mg TBAJ-876 oral suspension, fed
Midazolam
Day 1 and Day 20: Midazolam oral syrup: 2 mg, fasted
Digoxin
Day 2 and Day 21: Digoxin tablet: 0.25 mg, fasted
TLD
Day 1 and Day 20: fixed dose combination of dolutegravir 50 mg + tenofovir disoproxil fumarate 300 mg + lamivudine 300 mg, fasted

Locations

Country Name City State
United States TKL Research, Inc. Fair Lawn New Jersey

Sponsors (1)

Lead Sponsor Collaborator
Global Alliance for TB Drug Development

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary TBAJ-876 effect on the pharmacokinetics of the CYP-3A4 substrate midazolam and the inhibition potential of TBAJ-876 on P-gp in healthy adult subjects Geometric mean ratio of midazolam's area under the (plasma concentration vs. time) curve when co-administered with TBAJ-876 versus when administered alone, and similarly for the maximum concentration. Inference will be based on analysis of variance applied to log-transformed parameters. Day 1: pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours; Day 20: pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours
Primary TBAJ-876 effect on the pharmacokinetics of the P-gp substrate digoxin Geometric mean ratio of digoxin's area under the (plasma concentration vs. time) curve when co-administered with TBAJ-876 versus when administered alone, and similarly for the maximum concentration. Inference will be based on analysis of variance applied to log-transformed parameters. Day 2: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours; Day 21: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours
Secondary Number of Participants with Treatment-Related Adverse Events in Group 1 Population Subjects will be monitored for any adverse events from the signing of the consent form until the end-of-study visit. The Investigator or a Sub-Investigator will assess its relationship to the study drug. from date of the start of treatment to the end of study at 25 days
Secondary Number of Participants with Treatment-Related Adverse Events in Group 2 Population Subjects will be monitored for any adverse events from the signing of the consent form until the end-of-study visit. The Investigator or a Sub-Investigator will assess its relationship to the study drug. from date of the start of treatment to the end of the study at 25 days
See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT05526885 - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa N/A
Completed NCT04369326 - Community Initiated Preventive Therapy for TB N/A
Recruiting NCT04568967 - TB-CAPT EXULTANT - HIV N/A
Completed NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT04975178 - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa Phase 3
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03973970 - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting NCT04230395 - Alcohol Reduction Among People With TB and HIV in India N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Active, not recruiting NCT02906007 - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV Phase 1/Phase 2
Not yet recruiting NCT05917210 - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda N/A
Not yet recruiting NCT06017843 - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding N/A
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2